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time is high. Further research with a control group is
needed to determine costs specifically attributed to BTP.
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As pharmaceutical care progresses, pharmacists must con-
tinue to develop their qualitative and quantitative assess-
ment skills. Quality of life (QoL) assessment represents an
important part of the overall outcome evaluation in the
management of depressed patients. OBJECTIVE: The pur-
pose of this prospective study was to document the QoL
reported to community pharmacists by treated ambulatory
depressed patients. METHODS: Pharmacists collected de-
mographic, antidepressant, and SF-36 questionnaire data,
and verified each patient’s antidepressant treatment for at
least three consecutive months. Most patients received their
antidepressant drug as their only medication. RESULTS:
Fifty-seven patients completed SF-36 questionnaires and de-
mographic data forms under the supervision of their com-
munity pharmacists. Thirty-five patients were treated with
SSRI’s while 22 were treated with Non-SSRI’s. Patients re-
ceiving Non-SSRI’s were eight years older on average than
those receiving SSRI’s (P  0.05). Patients receiving SSRI’s
scored statistically higher on five SF-36 Scale scores, in-
cluding physical functioning, role-physical, general health,
vitality, and mental health. Physical component summary
(PCS) scores were statistically higher for SSRI patients
than Non-SSRI patients, with scores of 49.95 and 39.39,
respectively (P  0.05). Mental component summary
(MCS) scores were similar for SSRI patients and Non-
SSRI patients, with scores of 45.02 and 42.48, respec-
tively. CONCLUSION: Non-SSRI patients demonstrated
a statistically poorer QoL in the PCS and related Scale
scores, a finding which is consistent with their older
mean age. These data support the avoidance of Non-SSRI
therapy in older depressed patients. These data also com-
pare favorably with the findings documented in medical
care settings, demonstrating the utility of the SF-36 by
community pharmacists in their usual practice settings.
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Many health-related quality of life instruments are not
useful in clinical practice because of their length and
scoring algorithms. The brief Quality of Life With Mi-
graine (QOLWM) questionnaire was designed as a
screening tool for general use by migraineurs. OBJEC-
TIVE: To determine sensitivity to discriminate among
levels of headache frequency and severity, and medication
usage. METHODS: The previously validated QOLWM
asks about the frequency and impact of seven problem
areas. Migraineurs participated in a web-based survey of
demographic and headache characteristics, use of pre-
scription and non-prescription headache medications,
and quality of life. ANOVA analyses included 994 re-
spondents who completed all QOLWM items. RESULTS:
Patients experiencing a high frequency of headaches (P 
0.0001) and days with severe headaches (P  0.0003) in
the previous month also had significantly lower quality
of life (higher QOLWM Total Scores) than patients re-
porting less frequent and severe episodes. Compared to
patients without such problems, those reporting nausea
(P  0.016), distress with activity (P  0.0001) or light
(P  0.01) had lower QOLWM scores. Patients taking
prescription medications daily (P  0.0001), or who
took prescription drugs at the beginning or during a
headache (P  0.01) also had lower QOLWM scores
than patients who did not use prescription medications.
Patients who took medications only at the headache on-
set (P  0.0001) had lower QOLWM scores than people
who took medication daily. CONCLUSIONS: These
data suggest that the QOLWM could discriminate among
patients with varying headache severity and medication
usage. The QOLWM could be useful for headache assess-
ment in clinical practice.
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Instrument-based scores are often used as outcome mea-
sures. However, little is known about what changes in
scores mean in terms of a clinical assessment of improve-
ment or deterioration. OBJECTIVE: The purpose of this
study was to determine how much change in standard
symptom and HRQOL instrument scores represents a
clinically detectable improvement or deterioration for
schizophrenia patients. METHODS: The VA Coopera-
tive Study of Clozapine in Refractory Schizophrenia eval-
uated 423 patients with clozapine or haloperidol. Symp-
toms (PANSS) and quality of life (QLS) scales were
competed at baseline, 1.5, 3, 6, and 12 months. Changes
were calculated as percentage improvement and as
changes in a mean 7-point item scale based on clinicians’
ratings of patient status compared to baseline. RE-
SULTS: Based on clinician-assessed improvements from
baseline, PANSS scores improved by 21%; QLS scores by
